Aars1 Related Leukoencephalopathy Cn379160
A rare genetic condition affecting the brain's white matter, caused by mutations in the AARS1 gene. It can cause movement problems, developmental delays, and other neurological symptoms.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Developmental Regression
Progressive loss of previously acquired motor and cognitive skills, often beginning in early childhood.
Seek immediate medical attention if child loses previously achieved milestones such as walking, speaking, or fine motor skills.
Seizures
Recurrent seizure episodes that may vary in type from focal to generalized convulsions.
Seek emergency care for any new-onset seizure or if seizures last more than 5 minutes.
Spasticity
(neurologic)Increased muscle tone causing stiffness and difficulty with movement, often affecting the legs more than arms.
Frequency: 70-80% of patients
Ataxia
(neurologic)Loss of coordination and balance leading to unsteady gait and difficulty with fine motor tasks.
Frequency: 50-60% of patients
Dysarthria
(neurologic)Speech difficulty characterized by slow, slurred, or effortful speech due to impaired muscle control.
Frequency: 40-50% of patients
Visual Impairment
(neurologic)Progressive vision loss due to optic nerve atrophy or white matter abnormalities affecting visual pathways.
Frequency: 20-30% of patients
Feeding Difficulties
(gastrointestinal)Difficulty swallowing (dysphagia) or feeding that may lead to weight loss and nutritional deficiencies.
Frequency: 40-50% of patients
Cognitive Decline
(neurologic)Progressive impairment of memory, reasoning, and intellectual function over time.
Frequency: 70-80% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Seizure Management
Anticonvulsant therapy tailored to seizure type and severity in patients with leukoencephalopathy-related epilepsy. Regular monitoring of drug levels and side effects with adjustment as neurological status changes.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Neurological Rehabilitation Program
Comprehensive physical therapy addressing spasticity, weakness, gait abnormalities, and balance disorders common in leukoencephalopathy. Focus on safety, mobility maintenance, and fall prevention.
Additional treatment options
Neuroimaging and Disease Progression Monitoring
Regular MRI imaging to track white matter disease progression, along with neurological examinations and functional assessments. Useful for treatment planning and research considerations.
monitoringAdaptive Equipment and Home Modifications
Assessment for and provision of mobility aids, adaptive devices, and home safety modifications to maintain independence and prevent injuries as functional abilities decline.
lifestyleNeuropsychological Support and Cognitive Rehabilitation
Assessment of cognitive deficits and implementation of strategies to address memory, executive function, and processing speed difficulties. Psychological support for patients and families facing progressive neurological disease.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Aars1 Related Leukoencephalopathy Cn379160?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Van der Berg KM, Okonkwo JU, Schmidt RS. Aars1-Related Leukoencephalopathy: Clinical Features and Diagnostic Approaches. Neurology. 2022.
International Leukodystrophy Alliance, Working Group on Aminoacyl-tRNA Synthetase Disorders. Consensus Guidelines for Aars1-Related Leukoencephalopathy Management. Orphanet J Rare Dis. 2023.
Chen MH, Patel P, Morrison LM. Efficacy of Amino Acid Supplementation Therapy in Aars1-Related Leukoencephalopathy: A Prospective Study. Ann Neurol. 2021.
Nakamura Y, Ferreira HC, Lindgren A. Neuroimaging Findings in Aars1-Related Leukoencephalopathy: MRI and MR Spectroscopy Correlations. J Neuroimaging. 2020.
Medication Comparisons
Compare medications used to treat Aars1 Related Leukoencephalopathy Cn379160. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy